Zhai Yuan, Qiao Bo, Shen Xiu-Da, Gao Feng, Busuttil Ronald W, Cheng Genhong, Platt Jeffrey L, Volk Hans-Dieter, Kupiec-Weglinski Jerzy W
Department of Surgery, Division of Liver and Pancreas Transplantation, Dumont-UCLA Transplant Center, Los Angeles, CA 90095, USA.
Transplantation. 2008 Apr 15;85(7):1016-22. doi: 10.1097/TP.0b013e3181684248.
Although toll-like receptor 4 (TLR4) activation has been demonstrated to play a key role in the induction of intrahepatic inflammation, leading to hepatocellular damage in liver ischemia/reperfusion injury (IRI), the nature of TLR4 ligands generated during tissue injury remains to be elucidated. We hypothesized that endogenous TLR4 ligands, rather than endotoxin (lipopolysaccharide [LPS]), are instrumental in the activation of liver TLR4 leading to local inflammation response that culminates in ultimate organ IRI.
By using the LPS-neutralizing agent, recombinant bactericidal/permeability-increasing protein, we showed that the endotoxin blockade failed to protect mouse livers from warm IRI, as assessed by serum alanine aminotransferase levels, intrahepatic inflammatory gene induction profile, and liver pathology. The recombinant bactericidal/permeability-increasing protein did not cause any hepatocytoxicity by itself if injected into normal naive mice. Furthermore, we demonstrated that liver perfusates, generated by isolated liver perfusion system, contained LPS-independent, heat-sensitive protein molecules that activated macrophages to produce tumor necrosis factor (TNF)-alpha through TLR4 but not TLR2 pathway.
This study provides a definitive evidence that endogenous TLR4 ligands are critical in the pathogenesis of liver IRI.
尽管已证明Toll样受体4(TLR4)激活在肝内炎症诱导中起关键作用,导致肝缺血/再灌注损伤(IRI)中的肝细胞损伤,但组织损伤期间产生的TLR4配体的性质仍有待阐明。我们推测内源性TLR4配体而非内毒素(脂多糖[LPS])有助于激活肝脏TLR4,导致局部炎症反应,最终导致终末器官IRI。
通过使用LPS中和剂重组杀菌/通透性增加蛋白,我们发现内毒素阻断不能保护小鼠肝脏免受温缺血再灌注损伤,这通过血清丙氨酸转氨酶水平、肝内炎症基因诱导谱和肝脏病理学评估。如果将重组杀菌/通透性增加蛋白注射到正常未致敏小鼠体内,其本身不会引起任何肝细胞毒性。此外,我们证明,由离体肝脏灌注系统产生的肝脏灌注液含有不依赖LPS的热敏感蛋白分子,这些分子通过TLR4而非TLR2途径激活巨噬细胞以产生肿瘤坏死因子(TNF)-α。
本研究提供了确凿证据,表明内源性TLR4配体在肝脏IRI发病机制中起关键作用。